New stable high concentration formulations for anti-FXIa antibodies

摘要

The present invention relates to novel liquid pharmaceutical high concentration formulations particularly suitable for subcutaneous administration and stable as liquid formulations over a long period of time, comprising human antibodies against coagulation factor FXIa as active ingredient, in particular those described in WO2013167669. The invention also relates to lyophilisates of certain liquid formulations with reduced reconstitution time and also to the use of these formulations in the therapy and prevention of thrombotic or thromboembolic disorders.